Can Real-World data unlock clues to a deadly Post-Transplant complication?

NCT ID NCT07732361

Completed Knowledge-focused Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study looks back at medical records of children and adults who developed a serious blood-clotting condition called thrombotic microangiopathy (TMA) within a year after a stem cell transplant. Researchers aim to understand survival rates and causes of death in these patients, whether or not they received a specific treatment. The goal is to gather real-world evidence that could guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANT THROMBOTIC MICROANGIOPATHY

Contacts and locations

Locations

Research Facility

Boston, Massachusetts, 02215, United States
Research Facility

Akron, Ohio, 44308, United States
Research Facility

Salt Lake City, Utah, 84108, United States
Research Facility

Brussels, Brussels Capital, 1020, Belgium
Research Facility

Liège, 1020, Belgium
Research Facility

Fortaleza, Ceará, 60430-372, Brazil
Research Facility

Brasília, Federal District, 70684-831, Brazil
Research Facility

Curitiba, Paraná, 80060-900, Brazil
Research Facility

Recife, Pernambuco, 52010-010, Brazil
Research Facility

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Research Facility

Jaú, São Paulo, 17210-120, Brazil
Research Facility

Rio de Janeiro, 20230-130, Brazil
Research Facility

São Paulo, 04023-064, Brazil
Research Facility

São Paulo, 05403-000, Brazil
Research Facility

São Paulo, 05410-030, Brazil
Research Facility

São Paulo, 15090-000, Brazil
Research Facility

Pessac, Gironde, 33604, France
Research Facility

Toulouse, Haute Garonne, 31059, France
Research Facility

Grenoble, Isere, 38043, France
Research Facility

Paris, 75475, France
Research Facility

Thessaloniki, Central Macedonia, 57010, Greece
Research Facility

Pátrai, West Greece, 26500, Greece
Research Facility

Rome, Lazio, 00168, Italy
Research Facility

Ancona, 60126, Italy
Research Facility

Brescia, 25123, Italy
Research Facility

Florence, 50134, Italy
Research Facility

Genova, 16147, Italy
Research Facility

Naples, 80123, Italy
Research Facility

Pavia, 27100, Italy
Research Facility

Roma, 00165, Italy
Research Facility

Torino, 10126, Italy
Research Facility

Fukushima, Fukushima, 960-1295, Japan
Research Facility

Tsukuba, Ibaraki, 305-8576, Japan
Research Facility

Saitama-shi, Saitama, 330-8777, Japan
Research Facility

Wakayama, Wakayama, 641-8510, Japan
Research Facility

Seoul, 03080, South Korea
Research Facility

Seoul, 05505, South Korea
Research Facility

Seoul, 06351, South Korea
Research Facility

Barcelona, 08041, Spain
Research Facility

Barcelona, 08950, Spain
Research Facility

London, Greater London, W12 0HS, United Kingdom
Research Facility

Newcastle, Tyne & Wear, NE1 4LP, United Kingdom
Research Facility

Birmingham, West Midlands, B4 6NH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.